11:07AM ET 1/11/2022 MT NewswiresTorrid Holdings (CURV) has an average rating of buy and price targets ranging from $12 to $25, according to analysts polled by Capital IQ. (MT Newswires...
2:24PM ET 1/10/2022 MT NewswiresAmicus Therapeutics (FOLD) forecast full-year 2022 sales from Galafold, or migalastat, for the treatment of Fabry disease will be in the range of $350...
9:42AM ET 1/10/2022 MT NewswiresTorrid Holdings (CURV) said Monday it now expects fiscal Q4 net sales to range from $300 million to $305 million, compared with its prior guidance of $325...
9:27AM ET 12/27/2021 MT NewswiresTorrid Holdings (CURV) has an average rating of buy and price targets ranging from $12 to $28, according to analysts polled by Capital IQ. (MT Newswires...
8-K 
